Bill
LC 2023
Overview: LC 2023 is a bill that would revise the termination related to the prohibition on the identification of 340B drugs.Purpose and Intent: The purpose of this bill is to addr
Overview: LC 2023 is a bill that would revise the termination related to the prohibition on the identification of 340B drugs.
Purpose and Intent: The purpose of this bill is to address the termination of the prohibition on the identification of 340B drugs, which are discounted drugs provided to certain healthcare facilities and organizations under the 340B Drug Pricing Program.
Key Provisions:
- Revises the termination date of the prohibition on the identification of 340B drugs
- Potentially extends or removes the termination date, depending on the specific changes made in the bill
Affected Parties and Impacts: This bill would primarily affect healthcare providers and organizations that participate in the 340B Drug Pricing Program, as well as the pharmaceutical companies that provide the discounted drugs. The changes to the termination date could impact the availability and pricing of 340B drugs for these entities.
Procedural and Timeline Considerations: This bill is listed as a "Draft Died in Process," indicating that it did not progress through the legislative process and was not enacted into law.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
